Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M
May 24, 2021 at 11:03 am
Bob Azelby. (Eliem Photo)
New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The fresh funding comes just two months after Eliem raised a $80 million round.
The pipeline: Founded in 2019, the company has two lead drug candidates in development: ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures. Both are in Phase 2a clinical trials.
ETX-810 is described as an investigational non-opioid that uses the palmitoylethanolamide (PEA) pathway to influence neuroinflammation and pain signaling. ETX-155 is an neuroactive steroid that acts as a GABA
Sana Biotechnology went public before testing any treatments in people.
The cell and gene therapy startup won t launch clinical trials for at least a year.
Noted life sciences VCs Flagship Pioneering and Arch Venture Partners were its biggest shareholders pre-IPO.
Cell and gene editing startup Sana Biotechnology s shares jumped more than 40% on its first day of trading, making one of its investors stakes worth more than $1.5 billion.
The company sold 23.5 million shares at $25 apiece Thursday. Its stock price was up 40.40% at the end of the first day of trading, closing at $35.10 per share. Sana will have about 185 millions shares outstanding after the IPO, valuing the company at $6.5 billion.